RecruitingNCT06648317
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
Sponsor
Peking University Cancer Hospital & Institute
Enrollment
20 participants
Start Date
Nov 21, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with lung lesions.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new type of PET/CT imaging scan using a radioactive tracer that targets a protein called Nectin-4, which is found on certain tumors. Researchers hope to use this scan to better identify and stage lung lesions (suspicious spots in the lungs).
**You may be eligible if...**
- You are 18–75 years old
- You have at least one measurable tumor or lesion
- Your doctor has recommended a PET/CT scan for cancer staging or diagnosis
- You have normal heart function
- You are expected to survive at least 12 weeks
**You may NOT be eligible if...**
- You have serious liver abnormalities
- You are pregnant or of childbearing age and unwilling to use contraception
- You are unable to follow study procedures
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERFDG-PET
All study participants will undergo 18F-FDG PET/CT scan within 1 week
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06648317
Related Trials
Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery
NCT075003761 location
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
NCT074051903 locations
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
NCT056283761 location
SL-28 for Advanced Solid Tumours
NCT073417371 location
A Phase II Study of SKB571 in Patients With Lung Cancer
NCT072304052 locations